Multi-therapies in androgenetic alopecia: review and clinical experiences
- PMID: 27424565
- DOI: 10.1111/dth.12390
Multi-therapies in androgenetic alopecia: review and clinical experiences
Abstract
Androgenetic alopecia (AGA) is a genetically determined progressive hair-loss condition which represents the most common cause of hair loss in men. The use of the medical term androgenetic alopecia reflects current knowledge about the important role of androgens and genetic factors in its etiology. In addition to androgen-dependent changes in the hair cycle, sustained microscopic follicular inflammation contributes to its onset. Furthermore, Prostaglandins have been demonstrated to have the ability in modulating hair follicle cycle; in particular, PGD2 inhibits hair growth while PGE2/F2a promote growth. Due to the progressive nature of AGA, the treatment should be started early and continued indefinitely, since the benefit will not be maintained upon ceasing therapy. To date, only two therapeutic agents have been approved by the Food and Drug Administration and European Medicines Agency for the treatment of AGA: topical minoxidil and oral finasteride. Considering the many pathogenetic mechanisms involved in AGA, various treatment options are available: topical and systemic drugs may be used and the choice depends on various factors including grading of AGA, patients' pathological conditions, practicability, costs and risks. So, the treatment for AGA should be based on personalized therapy and targeted at the different pathophysiological aspects of AGA.
Keywords: alopecia; dermatopathology; therapy-topical.
© 2016 Wiley Periodicals, Inc.
Similar articles
-
Controversies in the treatment of androgenetic alopecia: The history of finasteride.Dermatol Ther. 2019 Mar;32(2):e12647. doi: 10.1111/dth.12647. Epub 2018 Sep 25. Dermatol Ther. 2019. PMID: 30253001
-
Androgenetic alopecia: an evidence-based treatment update.Am J Clin Dermatol. 2014 Jul;15(3):217-30. doi: 10.1007/s40257-014-0077-5. Am J Clin Dermatol. 2014. PMID: 24848508 Review.
-
A review of the treatment of male pattern hair loss.Expert Opin Pharmacother. 2020 Apr;21(5):603-612. doi: 10.1080/14656566.2020.1721463. Epub 2020 Feb 17. Expert Opin Pharmacother. 2020. PMID: 32066284 Review.
-
Dutasteride in Androgenetic Alopecia: An Update.Curr Clin Pharmacol. 2017;12(1):31-35. doi: 10.2174/1574884712666170310111125. Curr Clin Pharmacol. 2017. PMID: 28294070 Review.
-
A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2257-2263. doi: 10.1111/jdv.15171. Epub 2018 Jul 20. J Eur Acad Dermatol Venereol. 2018. PMID: 29972712 Clinical Trial.
Cited by
-
Growth Factor Cocktail Including Fibroblast Growth Factor 9 (Cellcurin) in the Treatment of Androgenetic Alopecia in Men and Women: A Randomized Controlled Trial.Int J Trichology. 2023 Jul-Aug;15(4):133-143. doi: 10.4103/ijt.ijt_39_21. Epub 2024 Apr 5. Int J Trichology. 2023. PMID: 38765719 Free PMC article.
-
Study on the Efficacy and Potential Mechanism of Topical Shen Bai Hair Growing Decoction against Androgenetic Alopecia Based on Ultrahigh Performance Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry and RNA-seq.ACS Omega. 2024 Feb 26;9(9):10834-10851. doi: 10.1021/acsomega.3c09648. eCollection 2024 Mar 5. ACS Omega. 2024. PMID: 38463254 Free PMC article.
-
Non-invasive assessment of hair regeneration in androgenetic alopecia mice in vivo using two-photon and second harmonic generation imaging.Biomed Opt Express. 2023 Oct 19;14(11):5870-5885. doi: 10.1364/BOE.503312. eCollection 2023 Nov 1. Biomed Opt Express. 2023. PMID: 38021124 Free PMC article.
-
Combination of adipose-derived stem cell conditioned media and minoxidil for hair regrowth in male androgenetic alopecia: a randomized, double-blind clinical trial.Stem Cell Res Ther. 2023 Aug 21;14(1):210. doi: 10.1186/s13287-023-03440-2. Stem Cell Res Ther. 2023. PMID: 37605227 Free PMC article. Clinical Trial.
-
CBD: A Potential Lead against Hair Loss, Alopecia, and its Potential Mechanisms.Curr Drug Discov Technol. 2024;21(2):e200723218949. doi: 10.2174/1570163820666230720153607. Curr Drug Discov Technol. 2024. PMID: 37475557 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous